All In Biotech

Drug Trial Radar · NCT04945460

A Study of Sotatercept for the Treatment of Cpc-PH Due to HFpEF (MK-7962-007/A011-16)

A Phase 2, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Effects of Sotatercept Versus Placebo for the Treatment of Combined Postcapillary and Precapillary Pulmonary Hypertension (Cpc-PH) Due to Heart Failure With Preserved Ejection Fraction (HFpEF)

Last checked: Nov 20, 2026Latest source record: Sep 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 165 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

165

Actual

Start

Dec 29, 2021

Primary completion

Sep 5, 2025

Study completion Apr 9, 2026

Sponsor

Sponsor type
Industry
First posted
Jun 30, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 2, double-blind, randomized, placebo-controlled study to evaluate the efficacy and safety of sotatercept versus placebo in adults with Cpc-PH due to HFpEF. The objective of this study is to evaluate the efficacy, safety and tolerability of sotatercept versus placebo in adults with Cpc-PH due to HFpEF. Efficacy is measured by change from baseline in pulmonary vascular resistance (PVR, primary endpoint) and 6-minute walk distance (6MWD, key secondary endpoint).

Conditions

  • Hypertension, Pulmonary

Interventions

  • Sotatercept 0.3 mg/kgDrug

    Administered by subcutaneous injection. Sotatercept (ACE-011) is a recombinant fusion protein consisting of the extracellular domain of the human activin receptor type IIA linked to the Fc piece of human IgG1.

  • PlaceboDrug

    Administered by subcutaneous injection

  • Sotatercept 0.3 mg/kg escalating to 0.7 mg/kgDrug

    Administered by subcutaneous injection. Sotatercept (ACE-011) is a recombinant fusion protein consisting of the extracellular domain of the human activin receptor type IIA linked to the Fc piece of human IgG1.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Base Study: Change From Baseline in Pulmonary Vascular Resistance (PVR) at Week 24Time frame: Baseline and Week 24

Locations

119 sites in 12 countries. Site status is shown where the registry gives one.

  • PULMONARY ASSOCIATES, P.A. ( Site 1008)

    Phoenix, Arizona

  • University of Arizona ( Site 1006)

    Tucson, Arizona

  • Scripps Clinic ( Site 4001)

    La Jolla, California

  • Cedars Sinai Medical Center ( Site 1082)

    Los Angeles, California

  • University of California Irvine ( Site 1086)

    Orange, California

  • Jeffrey S.Sager MD Medical Corporation ( Site 1060)

    Santa Barbara, California

  • Stanford University ( Site 1024)

    Stanford, California

  • Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center ( Site 1028)

    Torrance, California

  • University Of Colorado ( Site 1013)

    Aurora, Colorado

  • South Denver Cardiology Associates ( Site 1091)

    Littleton, Colorado

  • Winchester Chest Clinic ( Site 1093)

    New Haven, Connecticut

  • The George Washington University Medical Faculty Associates ( Site 1025)

    Washington D.C., District of Columbia

  • Bay Area Cardiology ( Site 1071)

    Brandon, Florida

  • Mayo Clinic Jacksonville - PPDS ( Site 1045)

    Jacksonville, Florida

  • AdventHealth Orlando ( Site 1058)

    Orlando, Florida

  • Tampa General Hospital ( Site 1043)

    Tampa, Florida

  • Piedmont Atlanta Hospital ( Site 1085)

    Atlanta, Georgia

  • Emory University ( Site 1030)

    Atlanta, Georgia

  • Saint Alphonsus Regional Medical Center ( Site 1097)

    Boise, Idaho

  • University of Illinois Hospital ( Site 1095)

    Chicago, Illinois

  • IU Health Advanced Heart and Lung Care ( Site 1092)

    Indianapolis, Indiana

  • Ascension Medical Group St. Vincent ( Site 1076)

    Indianapolis, Indiana

  • University of Iowa Hospital and Clinics ( Site 1050)

    Iowa City, Iowa

  • University of Kansas Medical Center ( Site 1020)

    Kansas City, Kansas

  • Norton Pulmonary Specialists ( Site 1066)

    Louisville, Kentucky

  • University of Louisville ( Site 1099)

    Louisville, Kentucky

  • University Medical Center New Orleans ( Site 1057)

    New Orleans, Louisiana

  • Tufts Medical Center - PPDS ( Site 1012)

    Boston, Massachusetts

  • Brigham and Women's Hospital [Boston, MA] ( Site 1014)

    Boston, Massachusetts

  • University of Michigan ( Site 1011)

    Ann Arbor, Michigan

  • University of Minnesota Hospitals ( Site 1062)

    Minneapolis, Minnesota

  • Washington University School of Medicine [Saint Louis, MO] ( Site 1022)

    St Louis, Missouri

  • University of Nebraska Medical Center ( Site 1053)

    Omaha, Nebraska

  • Pulmonary Health Physicians ( Site 1080)

    Liverpool, New York

  • Weill Cornell Medical College ( Site 1046)

    New York, New York

  • University of Rochester Medical Center - PPDS ( Site 1039)

    Rochester, New York

  • Duke University Medical Center ( Site 1026)

    Durham, North Carolina

  • The Carl and Edyth Lindner Center for Research and Education at the Christ Hospital ( Site 1001)

    Cincinnati, Ohio

  • University Hospitals Cleveland Medical Center ( Site 1005)

    Cleveland, Ohio

  • Cleveland Clinic Foundation ( Site 1065)

    Cleveland, Ohio

Showing 40 of 119 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.